Loading…
← CockpitCompetitor Analysis › 603883.SS LBX Pharmacy Chain Joint Stock Company Class AOpen in the cockpit ↗

LBX Pharmacy Chain Joint Stock Company Class A603883.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Drugstore Chains

Major Chinese retail pharmacy chain ('Laobaixing'), one of the country's largest drugstore networks.

≈ A China-focused CVS/WalgreensMomentum leader 96
Mkt cap
$1.71B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$29.9M
20-day average traded
Fwd P/E
16.1×
forward earnings
ROIC−WACC
+6.8 pp
WACC 5.8%
Hurdle
-20 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥14.91
1D0.0%
1W+4.7%
1M+1.6%
3M+10.9%
6M+12.9%
YTD+0.7%
1Y-11.6%
ATR %3.0%
52w lowhigh17.0% off high

What LBX Pharmacy Chain Joint Stock does

Major Chinese retail pharmacy chain ('Laobaixing'), one of the country's largest drugstore networks.

Earns by buying medicines and health products from suppliers and reselling them through its stores, often paid for through state medical-insurance accounts. Growth has come largely from opening new stores and buying local chains, and the group's home base is Changsha in Hunan.

In one line: A China-focused CVS/Walgreens.

Products and services

  • Retail pharmacy stores

Customers

  • Retail/patient consumers

Where it sits in the supply chain

  • Consumer Staples
  • Pharmacy retail
  • Drugstore chains

What could go right

  • Pharmacy-chain consolidation
  • Aging-population drug demand

What could go wrong

  • Drug-pricing/centralized procurement policy
  • Chain price competition

Moat: narrow (scale, distribution, regulatory licence). One of China's largest pharmacy networks, giving procurement scale over independents.

Headquarters: Changsha, Hunan, China · Employees: 36,892

Named competitors

LBX Pharmacy Chain Joint Stock at a glance

Size LBX Pharmacy Chain Joint Stock (603883.SS) is a China Consumer Staples company (Drugstore Chains) with a market value of $1.71B, the 1341st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.91 on 18 Nov 2026.

Performance Over six months the shares gained 12.9%, against +2.6% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 17 in its peer set.

Growth Revenue grew 2.8% over the last twelve months (peer median +6.2%); the operating margin is 4.9% (peer median 4.8%).

Valuation It trades at 16.1× forward earnings against a peer median of 16.6× (6th cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -20 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.8 points above its cost of capital (5.8% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026603883.SS 117Peer median 104
Six months, rebased to 100: LBX Pharmacy Chain Joint Stock against the median of its 16 peers (local-currency closes).

LBX Pharmacy Chain Joint Stock financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥22.8BCN¥22.2BCN¥22.3BCN¥22.4BCN¥20.1B
Revenue growth—-1%0%+11%—
Gross profitCN¥7.33BCN¥5.52BCN¥7.21BCN¥5.80BCN¥5.09B
EBITDAn/aCN¥2.65BCN¥2.78BCN¥2.90BCN¥2.70B
Net incomeCN¥471MCN¥382MCN¥519MCN¥929MCN¥785M
Free cash flowCN¥3.02BCN¥2.89BCN¥1.52BCN¥2.12BCN¥2.02B
Capital expenditureCN¥165MCN¥253MCN¥508MCN¥621MCN¥308M
Total debtCN¥8.10BCN¥9.57BCN¥10.3BCN¥9.86BCN¥10.1B

Quarterly statements and history in the cockpit →

LBX Pharmacy Chain Joint Stock competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-10%0%+10%314896279989GRDN7649603233MEDPLUS301408926730101760393926643034603590002788603883.SS6-month return →1-month return →
Up and to the right = strong over both horizons. LBX Pharmacy Chain Joint Stock is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×96270027279989GRDN7649603233MEDPLUS92673034603590603883.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. LBX Pharmacy Chain Joint Stock is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%314896270027279989GRDN7649603233MEDPLUS30140830101726643034603590002788603883.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. LBX Pharmacy Chain Joint Stock is the large dot.

LBX Pharmacy Chain Joint Stock competitors and peer comparison

Head to head with its named competitors (603883.SS vs 603939.SS vs 603233.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
LBX Pharmacy Chain Joint Stock 603883.SS$1.71B+13%+3%5%16.1×-10.7%
Yifeng Pharmacy Chain 603939.SS$4.84B+16%+5%10%17.2×-9.3%
DaShenLin Pharmaceutical 603233.SS$3.64B+10%+7%8%15.9×-9.5%

How LBX Pharmacy Chain Joint Stock compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LBX Pharmacy Chain Joint Stock against its 16 peers (data as of 18 Nov 2026)
Measure603883.SSPeer medianRank in peer set
1-month return+1.6%+2.1%9th highest of 17
6-month return+12.9%+2.6%5th highest of 17
Distance from 52-week high-17.0%-15.2%9th highest of 17
Revenue growth (TTM)+2.8%+6.2%4th lowest of 17
Operating margin4.9%4.8%8th highest of 17
Forward P/E16.1×16.6×6th cheapest of 12
Growth the price implies (Req g, 7 yrs)-10.7%-7.3%4th least demanding of 16
Growth delivered (Del g)+9.7%+12.4%7th lowest of 16
Hurdle (Req g minus delivered)-20.4 pp-19.5 pp7th least demanding of 16
ROIC minus cost of capital+6.8 pp+7.1 pp8th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%16.6×-16.0%+6.5%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%33.9×18.6%+17.6%
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%n/a-7.5%+23.3%
Genky DrugStores 9267.TJapan$728M+3%+8%5%13.9×n/an/a
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%n/a1.1%+17.4%
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%
Cawachi 2664.TJapan$562M+31%-1%2%n/a-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%10.5×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%19.0×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%n/a-0.4%+6.5%

Questions

Who are LBX Pharmacy Chain Joint Stock's main competitors?
Named competitors: Yifeng Pharmacy Chain (603939.SS), DaShenLin Pharmaceutical Group (603233.SS). The cockpit's measured peer set (industry) also includes Create SD (3148.T), Ain (9627.T), Yixintang Pharmaceutical (002727.SZ), Sundrug (9989.T), Guardian Pharmacy Services (GRDN), Sugi (7649.T).
Is LBX Pharmacy Chain Joint Stock expensive compared with its peers?
On forward p/e it trades at 16.1× against a peer median of 16.6×, 6th cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -20 pp: the price already allows for a slowdown.
How has LBX Pharmacy Chain Joint Stock stock performed?
Over six months to 18 Nov 2026 the shares returned +12.9% against +2.6% for the median peer; over one year -11.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.